Identification of C/EBPδ-Modifying Compounds as Potential Anticancer Agents Using a High-Throughput Drug Screen.

ABSTRACT: CCAAT/enhancer-binding protein delta (C/EBPδ) has been shown to promote tumour growth, drug resistance and metastasis formation in some cancers, whereas we have shown that its re-expression limits the features of tumour progression in pancreatic ductal adenocarcinoma (PDAC). The pharmacological targeting-either activation or inhibition-of C/EBPδ may therefore harbour clinical relevance and is desirable for preclinical studies on C/EBPδ in different contexts. Regrettably, to date, only few molecules have been identified that modify C/EBPδ. Here, we present a high-throughput compound screen in conjunction with a novel eGFP reporter to identify further compounds that either increase or decrease C/EBPδ transcriptional activity. Of 1402 small molecule inhibitors, we identified a total of 22 pot

SUBMITTER: Hartl L 

PROVIDER: S-EPMC11783153 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature